Special Advisor Board
SCHMIDT Capital Advisors
We assembled the Special Advisor Board with some of the most knowledgeable and experienced professionals in the industry. They engage on a case-by-case basis, adding extra value to our clients and ensuring that you receive the best possible corporate finance advice.
Lene Gerlach
Special advisor
Lene Gerlach
Special advisor
Lene is a venture partner at Hadean Ventures, bringing over 25 years of experience in the life sciences industry. Her diverse background includes roles as a research scientist, patent attorney, business developer, and consultant for university spin-out companies. Lene has held key management positions in several biotech firms, including serving as Vice President at Action Pharma, which was acquired by Abbott in 2012, and at Visiopharm, a global AI healthcare company. Since 2014, she has been a venture capitalist, financing over 35 companies. Lene has also served as Chairman for 18 companies, reflecting her extensive board experience. She is the founder and Chair of Women in Life Science Denmark (WiLD), a non-profit network organization for executives and experts in the Life Science Industry, now counting more than 200 members from more than 130 companies and academic institutions.
Lene holds a M. Sc. in Human biology and a PhD in Neuroscience from the University of Copenhagen.
Lene is a venture partner at Hadean Ventures, bringing over 25 years of experience in the life sciences industry. Her diverse background includes roles as a research scientist, patent attorney, business developer, and consultant for university spin-out companies. Lene has held key management positions in several biotech firms, including serving as Vice President at Action Pharma, which was acquired by Abbott in 2012, and at Visiopharm, a global AI healthcare company. Since 2014, she has been a venture capitalist, financing over 35 companies. Lene has also served as Chairman for 18 companies, reflecting her extensive board experience. She is the founder and Chair of Women in Life Science Denmark (WiLD), a non-profit network organization for executives and experts in the Life Science Industry, now counting more than 200 members from more than 130 companies and academic institutions.
Lene holds a M. Sc. in Human biology and a PhD in Neuroscience from the University of Copenhagen.
John Haurum
Special advisor
John Haurum
Special advisor
John serves as a Non-Executive Director for several European biotech companies, including Adcendo, CatalYm, MC2 Therapeutics, Neophore, Saniona, Solid Therapeutics, and Synklino. From 2012 to 2018, he was the CEO of F-star in Cambridge, UK, where he initiated multiple clinical trials in oncology, and secured over €200 million in non-dilutive revenue. Prior to that, he was Vice President of Research at ImClone, NY (2010-2012), and Chief Scientific Officer and co-founder of Symphogen A/S in Denmark (2000-2009).
John holds an MD from Aarhus University and a D.Phil. in Immunology from the University of Oxford.
John serves as a Non-Executive Director for several European biotech companies, including Adcendo, CatalYm, MC2 Therapeutics, Neophore, Saniona, Solid Therapeutics, and Synklino. From 2012 to 2018, he was the CEO of F-star in Cambridge, UK, where he initiated multiple clinical trials in oncology, and secured over €200 million in non-dilutive revenue. Prior to that, he was Vice President of Research at ImClone, NY (2010-2012), and Chief Scientific Officer and co-founder of Symphogen A/S in Denmark (2000-2009).
John holds an MD from Aarhus University and a D.Phil. in Immunology from the University of Oxford.
Stephanie Anthon Storm
Special advisor
Stephanie Anthon Storm
Special advisor
Stephanie is a management consultant at the IT consulting firm 7N, where she plays a crucial role in driving strategic initiatives and enhancing operational efficiency across organizations. Her expertise lies in delivering tailored consulting services that address complex challenges organizations face. As part of 7N, she collaborates closely with clients to develop innovative solutions that align with their business goals and promote growth.
Prior to joining 7N, Stephanie worked at Accenture for 4 years as finance business partner, followed by 3 years as a Director in corporate finance advisory. In this role, she was responsible for devising and executing deals within Equity Capital Markets (ECM) and M&A, including IPOs, rights issues, and capital injections.
Stephanie holds an M.Sc. in Finance and Strategic Management from Copenhagen Business School.
Stephanie is a management consultant at the IT consulting firm 7N, where she plays a crucial role in driving strategic initiatives and enhancing operational efficiency across organizations. Her expertise lies in delivering tailored consulting services that address complex challenges organizations face. As part of 7N, she collaborates closely with clients to develop innovative solutions that align with their business goals and promote growth.
Prior to joining 7N, Stephanie worked at Accenture for 4 years as finance business partner, followed by 3 years as a Director in corporate finance advisory. In this role, she was responsible for devising and executing deals within Equity Capital Markets (ECM) and M&A, including IPOs, rights issues, and capital injections.
Stephanie holds an M.Sc. in Finance and Strategic Management from Copenhagen Business School.
Martin Stenfeldt
Special advisor
Martin Stenfeldt
Special advisor
Martin Stenfeldt is the co-founder and former CEO of MedTrace Pharma, an award-winning scaleup specializing in radiopharmaceuticals. He brings extensive experience across medical devices, digital health, and pharmaceuticals, having worked in both corporate and startup environments. Martin has also gained significant global exposure, having spent five years working in the US and Germany, where he expanded his network within the life science industry.
Currently, Martin is researching and writing a book on scaling life science ventures, where he interviews peers from the Nordics and the US to capture lessons learned and identify key success factors and patterns. In addition to his research, Martin is actively involved in mentoring startups and scaleups, and serves on the boards of young companies as well as a Residential Industry Fellow at the department of Entrepreneurship at the Technical University of Denmark.
Martin holds a M.Sc. in Business Administration and Marketing from Aarhus University.
Martin Stenfeldt is the co-founder and former CEO of MedTrace Pharma, an award-winning scaleup specializing in radiopharmaceuticals. He brings extensive experience across medical devices, digital health, and pharmaceuticals, having worked in both corporate and startup environments. Martin has also gained significant global exposure, having spent five years working in the US and Germany, where he expanded his network within the life science industry.
Currently, Martin is researching and writing a book on scaling life science ventures, where he interviews peers from the Nordics and the US to capture lessons learned and identify key success factors and growth patterns. In addition to his research, Martin is actively involved in mentoring startups and scaleups, and serves on the boards of young companies as well as a Residential Industry Fellow at the department of Entrepreneurship at the Technical University of Denmark.
Martin holds a M.Sc. in Business Administration and Marketing from Aarhus University.
Michael Mathiesen
Special advisor
Michael Mathiesen
Special advisor
Michael is the CEO of the Bambwa Group, bringing over 30 years of international business expertise with a focus on information technology, telecommunications, and eCommerce. He has played a pivotal role in more than 325 international investments across Europe, the US, Canada, Russia, the UAE, Taiwan, China, and West Africa, with two of these ventures achieving unicorn status. Michael has also been involved in 9 IPOs across Stockholm, Copenhagen, and London, and over 35 trade sales. He has served as a non-executive board member for more than 100 private, public, and government organizations globally, as well as on the board of the Young Presidents’ Organization (YPO).
Michael holds a HD in Intl. Business from CBS and completed the Wharton School Executive Program in Entrepreneurship.
Michael is the CEO of the Bambwa Group, bringing over 30 years of international business expertise with a focus on information technology, telecommunications, and eCommerce. He has played a pivotal role in more than 325 international investments across Europe, the US, Canada, Russia, the UAE, Taiwan, China, and West Africa, with two of these ventures achieving unicorn status. Michael has also been involved in 9 IPOs across Stockholm, Copenhagen, and London, and over 35 trade sales. He has served as a non-executive board member for more than 100 private, public, and government organizations globally, as well as on the board of the Young Presidents’ Organization (YPO).
Michael holds a HD in Intl. Business from CBS and completed the Wharton School Executive Program in Entrepreneurship.
Trine Ahlgreen
Special advisor
Trine Ahlgreen
Special advisor
Trine Ahlgreen is a seasoned life science leader with a strong track record in strategy creation and execution including go-to-market, portfolio optimization, market access, regulatory, and clinical program design. With 20 years of experience driving global and local commercial initiatives at Novo Nordisk, she successfully transitioned into biotech as Chief Business Officer for a Swiss biotech in dermatology, oncology and infectious diseases, where she has led the commercial function, fundraising (dilutive and non-dilutive) and built up a successful Business Development team.
Trine holds as M.Sc. in International Business from CBS.
Trine Ahlgreen is a seasoned life science leader with a strong track record in strategy creation and execution including go-to-market, portfolio optimization, market access, regulatory, and clinical program design. With 20 years of experience driving global and local commercial initiatives at Novo Nordisk, she successfully transitioned into biotech as Chief Business Officer for a Swiss biotech in dermatology, oncology and infectious diseases, where she has led the commercial function, fundraising (dilutive and non-dilutive) and built up a successful Business Development team.
Trine holds as M.Sc. in International Business from CBS.
Claus Bo Svendsen
Special advisor
Claus Bo Svendsen
Special advisor
Claus is a co-founder of Nasdaq-listed GH Research PLC. From 2017 to 2025, he was CEO of Forward Pharma that secured a $1.25 billion license agreement with Biogen in 2017. At Novo Nordisk, he led the Global Medical Affairs strategy for Victoza® and Saxenda®. Early in his career, he worked as a Medical Analyst. With a clinical focus on internal medicine, he received a Young Investigator Award from the Foundation for Sarcoidosis Research and authored more than 25 scientific publications. His expertise spans metabolism, neurological diseases, and psychiatry.
Claus holds an MD and PhD from the University of Copenhagen and an executive MBA from Copenhagen Business School.
Claus is a co-founder of Nasdaq-listed GH Research PLC. From 2017 to 2025, he was CEO of Forward Pharma that secured a $1.25 billion license agreement with Biogen in 2017. At Novo Nordisk, he led the Global Medical Affairs strategy for Victoza® and Saxenda®. Early in his career, he worked as a Medical Analyst. With a clinical focus on internal medicine, he received a Young Investigator Award from the Foundation for Sarcoidosis Research and authored more than 25 scientific publications. His expertise spans metabolism, neurological diseases, and psychiatry.
Claus holds an MD and PhD from the University of Copenhagen and an executive MBA from Copenhagen Business School.
Claude Mikkelsen.
Special advisor.
Contact
Claude is Director of Investor Relations in BB Biotech and a Director at Bellevue Asset Management (UK) Ltd. BB Biotech is listed in Switzerland and Germany and is one of the world’s largest investors in its sector. Investments are focused on listed companies developing and commercializing novel medical treatments and cures. Before joining BB Biotech in 2012, Claude created CMI Consulting to provide customized strategy, business development and financial services for biotech, pharmaceutical and medical device companies. Prior to that he served 5 years as Senior Vice President of Finance and Investor Relations in Pharmexa, a cancer vaccine company listed on the Copenhagen Stock Exchange.
Claude holds an M.Sc. in Business Administration and Law from Aalborg University.
Claude is Director of Investor Relations in BB Biotech and a Director at Bellevue Asset Management (UK) Ltd. BB Biotech is listed in Switzerland and Germany and is one of the world’s largest investors in its sector. Investments are focused on listed companies developing and commercializing novel medical treatments and cures. Before joining BB Biotech in 2012, Claude created CMI Consulting to provide customized strategy, business development and financial services for biotech, pharmaceutical and medical device companies. Prior to that he served 5 years as Senior Vice President of Finance and Investor Relations in Pharmexa, a cancer vaccine company listed on the Copenhagen Stock Exchange.
Claude holds an M.Sc. in Business Administration and Law from Aalborg University.
